CD22-Binding Antibodies for Precise Cancer and Autoimmune Targeting

The patent segments the therapeutic approach by developing antibodies that specifically target distinct epitopes on the CD22 protein (such as the Ig-like C2-type domains). This segmentation allows for precise targeting of CD22-expressing cells while sparing other cells, thereby improving therapeutic outcomes through specific binding rather than conventional non-specific treatments

The patent introduces CD22-specific antibodies as intermediary molecules that mediate between the therapeutic agent and the target cells. These antibodies serve as selective intermediaries that bind to CD22 on the surface of B-cell malignancies and autoimmune disease cells, enabling specific delivery of therapeutic effects (such as ADCP, CDC, or T-cell recruitment) only to CD22-positive cells

The patent employs universal CD22-specific antibody platforms that can be adapted for multiple therapeutic modalities including antibody-drug conjugates, radioimmunotherapy, and bispecific antibodies. These universal antibodies target conserved epitopes on CD22, allowing the same targeting mechanism to be used across different disease indications (B-cell malignancies, autoimmune diseases) and different therapeutic approaches, thereby reducing overall treatment complexity despite high initial precision

The patent optimizes antibody parameters such as isotype selection (IgG1, IgG2, IgG3, IgG4), affinity constants, and epitope specificity to achieve precise CD22 targeting. By carefully adjusting these parameters, the patent achieves high targeting precision while maintaining manageable treatment complexity through systematic optimization rather than ad-hoc approaches